Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Simcere Pharmaceutical Group Limited ( (HK:2096) ) has issued an announcement.
Simcere Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of SIM0613, an LRRC15-targeting antibody-drug conjugate for advanced solid tumors, marking a key milestone for its oncology pipeline. SIM0613 is designed to selectively bind LRRC15, penetrate tumors deeply and deliver a cytotoxic payload to cancer cells and cancer-associated fibroblasts while sparing normal tissues, with preclinical models showing robust tumor regression.
The program’s progress builds on an exclusive licensing agreement between Simcere subsidiary Jiangsu Simcere Zaiming and Ipsen, under which Simcere could receive up to US$1.06 billion in upfront and milestone payments plus tiered royalties, while Ipsen assumes development and commercialization responsibilities outside Greater China. This latest regulatory clearance reinforces Simcere’s positioning as an emerging innovative oncology player and could unlock significant commercial and strategic value if SIM0613 advances successfully through clinical development.
The most recent analyst rating on (HK:2096) stock is a Buy with a HK$16.30 price target. To see the full list of analyst forecasts on Simcere Pharmaceutical Group Limited stock, see the HK:2096 Stock Forecast page.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is a Hong Kong–incorporated, innovation-driven pharmaceutical company with a strong focus on research and development. The group operates a State Key Laboratory dedicated to neurology and oncology drug development and concentrates on therapeutic areas including neuroscience, oncology, autoimmune diseases and anti-infective treatments, targeting current and future high unmet clinical needs through in-house R&D and strategic collaborations.
Average Trading Volume: 6,788,270
Technical Sentiment Signal: Buy
Current Market Cap: HK$30.91B
For an in-depth examination of 2096 stock, go to TipRanks’ Overview page.